PALI-2108 is an intestine-activated PDE4 inhibitor prodrug with positive Phase 1 data, and Palisade plans a Phase 2 IND for ASCENTRA-CD in 2H 2026. Oppenheimer projects long-term peak U.S. sales of $2.6B in UC (2040) and $2.8B in fibrostenotic CD (2041); a Buy on PALI supports a multi-year re-rating if Phase 2 data align with early signals. Near-term moves may reflect momentum around IND timing and trial progress.
PALI stock traded 51.5% higher at $2.12. Palisade Bio raised $5 million via a public offering. PALI-2108 showed promising safety results in Phase 1 trials. Preliminary data indicates favorable pharmacokinetics for PALI-2108. Company has $8 million cash, funding through Q1 2025.
